1. What is the Chemxpert database?

Chemxpert database is a techno-commercial information platform developed and operated by Lifescience Intellipedia Pvt. Ltd. Our data provides valuable insights regarding sourcing, marketing, development, and regulatory functions for the entire Lifescience industry. The different industries covered by our data encompass APIs, FDFs, pharma intermediates, paints, dyes, polymers, biotechnology, biochemical, food additives, nutraceuticals, etc.

2. How can I subscribe to the Chemxpert database?

You can gain access to the Chemxpert database after subscribing to it by visiting this link: - https://chemxpert.com/pricing

3. How many countries' data is available on your portal?

The Chemxpert database covers more than 200 countries. We are working in the direction of expanding our data coverage in more countries.

4. What are the different sources you use for obtaining information?

The different sources we use for data collection are as follows: - • Primary researc • DMF, ANDA, & CEP list • Conferences, Exhibitions, & Tradeshow • Company annual reports • DMF, ANDA, & CEP list • Subject matter experts & KOL survey. Apart from these, our other valuable sources include application-wise manufacturers list, subscribed and non-subscribed databases, corporate partners, US FDA Orange book, publicly available sources, industry associates, national statistics, regulatory websites, etc. You can gain access to the Chemxpert database after subscribing to it by visiting this link: -https://chemxpert.com/sources

5. What is the expected time for account activation?

Your Chemxpert account will be activated instantly if the payment is made through our website. If you choose to use RTGS, NEFT, or IMPS systems for payment, your account will be activated within 24 hours.

16 Dec 2021
Admin
News Article

Glenmark Looks To License Out Second Drug Asset

Glenmark Chairman And Managing Director Glenn Saldanha Said One Of The Corporate Objectives Of The Mumbai-Headquartered Company Is To Do At Least One Or Two Licensing Deals From Its Innovative Pipeline In Fy21.Drug Maker Glenmark Is In Discussions With Some Global Peers To License Out A Second Potential Drug Asset, Isb 830, From Its Us-Based Clinical Stage Biotech Subsidiary Ichnos Sciences Days After Concluding An Out-Licensing Deal With Spanish Firm Almirall. Glenmark Chairman And Managing Director Glenn Saldanha Said One Of The Corporate Objectives Of The Mumbai-Headquartered Company Is To Do At Least One Or Two Licensing Deals From Its Innovative Pipeline In Fy21.Monoclonal Antibody Used To Treat A Skin Disease Called Atopic Dermatitis - Has Completed The Proof-Of-Concept Studies On Patients In The Us. Early This Week, Ichnos Had Entered Into An Exclusive Agreement With Almirall To Out-License Its Novel Monoclonal Antibody Therapy Isb 880, Used In Treatment Of Autoimmune Diseases. The Deal Involved Upfront Payment Of $25 Million In Addition To Development Milestone Payments And Royalties On Sales If The Drug Achieves Marketing Authorisation. Licensing Deals Are Nothing New For Glenmark. It Had Earlier Raised $250 Million Through Eight Out-Licensing Deals To Companies Including Merck, Eli Lilly, Sanofi And Forest Laboratories, But This Amount Does Not Cover All The Costs. And Much Of That Was Again Ploughed Back Into Drug Discovery. Self-Sustaining R&D Licensing Deals Are Critical For Glenmark'S Strategy Of Making Its Drug Discovery Activity Self-Sustaining. "We Are Working On One; We Will Continue To See Additional Licensing Deals And Income Streams, Which Will Make It Self-Sustaining," Saldanha Said. Glenmark Has Been Weighed Down By High R&D Expenses. The Company Each Year Spends Over $100 Million On Innovative Research, And The Spend Only Increases As The Assets Go For Late-Stage Clinical Trials, Which Call For Tests On A Large Number Of Patients Across Multiple Locations

Let’s apply Data-Driven Pricing to Your APIs

Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.

Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.

Start using market intelligence today and allow yourself to be in control in the API market.

Check it out today and make more informed sourcing decisions! Learn More!